135 related articles for article (PubMed ID: 9570999)
21. The effects of abdominal and bimanual pelvic examination and transvaginal ultrasonography on serum CA-125 levels.
Sari R; Buyukberber S; Sevinc A; Ates M; Balat O; Hascalik S; Turk M
Clin Exp Obstet Gynecol; 2000; 27(1):69-71. PubMed ID: 10758808
[TBL] [Abstract][Full Text] [Related]
22. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model.
Timmerman D; Bourne TH; Tailor A; Collins WP; Verrelst H; Vandenberghe K; Vergote I
Am J Obstet Gynecol; 1999 Jul; 181(1):57-65. PubMed ID: 10411796
[TBL] [Abstract][Full Text] [Related]
23. Serum CA 125 levels in preoperative evaluation of pelvic masses.
Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
[TBL] [Abstract][Full Text] [Related]
24. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer.
Hata K; Hata T; Manabe A; Sugimura K; Kitao M
Obstet Gynecol; 1992 Dec; 80(6):922-6. PubMed ID: 1448260
[TBL] [Abstract][Full Text] [Related]
25. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer.
Bourne TH; Campbell S; Reynolds K; Hampson J; Bhatt L; Crayford TJ; Whitehead MI; Collins WP
Gynecol Oncol; 1994 Mar; 52(3):379-85. PubMed ID: 8157195
[TBL] [Abstract][Full Text] [Related]
26. A combined approach for the early detection of ovarian cancer in asymptomatic women.
Adonakis GL; Paraskevaidis E; Tsiga S; Seferiadis K; Lolis DE
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 65(2):221-5. PubMed ID: 8730628
[TBL] [Abstract][Full Text] [Related]
27. [Preoperative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings. CA 125 in serum and menopausal status].
Hagen B; Tingulstad S; Onsrud M; Moen M; Kiserud T; Eik-Nes S; Halvorsen T; Nustad K
Tidsskr Nor Laegeforen; 1995 Mar; 115(7):820-2. PubMed ID: 7701488
[TBL] [Abstract][Full Text] [Related]
28. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
29. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease.
Malkasian GD; Knapp RC; Lavin PT; Zurawski VR; Podratz KC; Stanhope CR; Mortel R; Berek JS; Bast RC; Ritts RE
Am J Obstet Gynecol; 1988 Aug; 159(2):341-6. PubMed ID: 2457318
[TBL] [Abstract][Full Text] [Related]
30. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
31. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary.
Einhorn N; Knapp RC; Bast RC; Zurawski VR
Acta Oncol; 1989; 28(5):655-7. PubMed ID: 2590540
[TBL] [Abstract][Full Text] [Related]
32. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.
Jacobs IJ; Rivera H; Oram DH; Bast RC
Br J Obstet Gynaecol; 1993 Dec; 100(12):1120-4. PubMed ID: 8297846
[TBL] [Abstract][Full Text] [Related]
33. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.
Jacobs I; Oram D; Fairbanks J; Turner J; Frost C; Grudzinskas JG
Br J Obstet Gynaecol; 1990 Oct; 97(10):922-9. PubMed ID: 2223684
[TBL] [Abstract][Full Text] [Related]
34. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index.
Davies AP; Jacobs I; Woolas R; Fish A; Oram D
Br J Obstet Gynaecol; 1993 Oct; 100(10):927-31. PubMed ID: 8217976
[TBL] [Abstract][Full Text] [Related]
35. Correlation of findings on transvaginal sonography with serum CA 125 levels.
Troiano RN; Quedens-Case C; Taylor KJ
AJR Am J Roentgenol; 1997 Jun; 168(6):1587-90. PubMed ID: 9168732
[TBL] [Abstract][Full Text] [Related]
36. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound.
Valentin L
Ultrasound Obstet Gynecol; 1999 Nov; 14(5):338-47. PubMed ID: 10623994
[TBL] [Abstract][Full Text] [Related]
37. Women with a pelvic mass--when to perform an ultrasound.
Doed JR; Quinn MA; Rome R; Koh H
Aust N Z J Obstet Gynaecol; 1993 Nov; 33(4):404-7. PubMed ID: 8179554
[TBL] [Abstract][Full Text] [Related]
38. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Kramer BS; Gohagan J; Prorok PC; Smart C
Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
[TBL] [Abstract][Full Text] [Related]
39. CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods.
Maggino T; Sopracordevole F; Matarese M; Di Pasquale C; Tambuscio G
Eur J Gynaecol Oncol; 1987; 8(6):590-5. PubMed ID: 3319631
[TBL] [Abstract][Full Text] [Related]
40. Transvaginal sonography, color flow imaging, computed tomographic scanning, and CA 125 as a routine follow-up examination in women with pelvic tumor: detection of recurrent disease.
Weiner Z; Beck D; Brandes JM
J Ultrasound Med; 1994 Jan; 13(1):37-41. PubMed ID: 7636952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
